Shire gets CHMP nod for US Vpriv manufacturing facility
This article was originally published in Scrip
Shire has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) for the production of Vpriv (velaglucerase alfa) in its new, state-of-the-art manufacturing facility in Lexington, Massachusetts. Shire has been granted an expedited review, and expects a final decision from the European Commission soon. A US decision is expected in the first half of 2012.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.